Literature DB >> 29075956

Visceral Congestion in Heart Failure: Right Ventricular Dysfunction, Splanchnic Hemodynamics, and the Intestinal Microenvironment.

Vincenzo B Polsinelli1, Arjun Sinha1, Sanjiv J Shah2.   

Abstract

PURPOSE OF REVIEW: Visceral venous congestion of the gut may play a key role in the pathogenesis of right-sided heart failure (HF) and cardiorenal syndromes. Here, we review the role of right ventricular (RV) dysfunction, visceral congestion, splanchnic hemodynamics, and the intestinal microenvironment in the setting of right-sided HF. We review recent literature on this topic, outline possible mechanisms of disease pathogenesis, and discuss potential therapeutics. RECENT
FINDINGS: There are several mechanisms linking RV-gut interactions via visceral venous congestion which could result in (1) hypoxia and acidosis in enterocytes, which may lead to enhanced sodium-hydrogen exchanger 3 (NHE3) expression with increased sodium and fluid retention; (2) decreased luminal pH in the intestines, which could lead to alteration of the gut microbiome which could increase gut permeability and inflammation; (3) alteration of renal hemodynamics with triggering of the cardiorenal syndrome; and (4) altered phosphate metabolism resulting in increased pulmonary artery stiffening, thereby increasing RV afterload. A wide variety of therapeutic interventions that act on the RV, pulmonary vasculature, intestinal microenvironment, and the kidney could alter these pathways and should be tested in patients with right-sided HF. The RV-gut axis is an important aspect of HF pathogenesis that deserves more attention. Modulation of the pathways interconnecting the right heart, visceral congestion, and the intestinal microenvironment could be a novel avenue of intervention for right-sided HF.

Entities:  

Keywords:  Heart failure; Intestine; Microbiome; Right ventricle; Sodium–hydrogen exchanger 3; Venous congestion

Mesh:

Year:  2017        PMID: 29075956      PMCID: PMC5681876          DOI: 10.1007/s11897-017-0370-8

Source DB:  PubMed          Journal:  Curr Heart Fail Rep        ISSN: 1546-9530


  78 in total

Review 1.  Management of right ventricular failure in the era of ventricular assist device therapy.

Authors:  Michael L Craig
Journal:  Curr Heart Fail Rep       Date:  2011-03

Review 2.  Oxygen metabolism and barrier regulation in the intestinal mucosa.

Authors:  Louise E Glover; J Scott Lee; Sean P Colgan
Journal:  J Clin Invest       Date:  2016-08-08       Impact factor: 14.808

3.  Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis.

Authors:  W H Wilson Tang; Zeneng Wang; Yiying Fan; Bruce Levison; Jennie E Hazen; Lillian M Donahue; Yuping Wu; Stanley L Hazen
Journal:  J Am Coll Cardiol       Date:  2014-10-27       Impact factor: 24.094

4.  Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis.

Authors:  J Vlachogiannakos; A S Saveriadis; N Viazis; I Theodoropoulos; K Foudoulis; S Manolakopoulos; S Raptis; D G Karamanolis
Journal:  Aliment Pharmacol Ther       Date:  2009-02-07       Impact factor: 8.171

5.  Concomitant renal and hepatic dysfunctions in chronic heart failure: clinical implications and prognostic significance.

Authors:  Gerhard Poelzl; Michael Ess; Andreas Von der Heidt; Michael Rudnicki; Matthias Frick; Hanno Ulmer
Journal:  Eur J Intern Med       Date:  2012-12-23       Impact factor: 4.487

Review 6.  Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications.

Authors:  Francesca Romana Ponziani; Viviana Gerardi; Silvia Pecere; Francesca D'Aversa; Loris Lopetuso; Maria Assunta Zocco; Maurizio Pompili; Antonio Gasbarrini
Journal:  World J Gastroenterol       Date:  2015-11-21       Impact factor: 5.742

7.  Intestinal inhibition of the Na+/H+ exchanger 3 prevents cardiorenal damage in rats and inhibits Na+ uptake in humans.

Authors:  Andrew G Spencer; Eric D Labonte; David P Rosenbaum; Craig F Plato; Christopher W Carreras; Michael R Leadbetter; Kenji Kozuka; Jill Kohler; Samantha Koo-McCoy; Limin He; Noah Bell; Jocelyn Tabora; Kristin M Joly; Marc Navre; Jeffrey W Jacobs; Dominique Charmot
Journal:  Sci Transl Med       Date:  2014-03-12       Impact factor: 17.956

8.  Choline Diet and Its Gut Microbe-Derived Metabolite, Trimethylamine N-Oxide, Exacerbate Pressure Overload-Induced Heart Failure.

Authors:  Chelsea L Organ; Hiroyuki Otsuka; Shashi Bhushan; Zeneng Wang; Jessica Bradley; Rishi Trivedi; David J Polhemus; W H Wilson Tang; Yuping Wu; Stanley L Hazen; David J Lefer
Journal:  Circ Heart Fail       Date:  2015-12-23       Impact factor: 8.790

9.  Association between Use of Oral Anti-Diabetic Drugs and the Risk of Sepsis: A Nested Case-Control Study.

Authors:  Chia-Jen Shih; Yueh-Lin Wu; Pei-Wen Chao; Shu-Chen Kuo; Chih-Yu Yang; Szu-Yuan Li; Shuo-Ming Ou; Yung-Tai Chen
Journal:  Sci Rep       Date:  2015-10-14       Impact factor: 4.379

Review 10.  Far from the eyes, close to the heart: dysbiosis of gut microbiota and cardiovascular consequences.

Authors:  Matteo Serino; Vincent Blasco-Baque; Simon Nicolas; Remy Burcelin
Journal:  Curr Cardiol Rep       Date:  2014-11       Impact factor: 2.931

View more
  13 in total

1.  First-in-human experience with occlusion of the superior vena cava to reduce cardiac filling pressures in congestive heart failure.

Authors:  Navin K Kapur; Richard H Karas; Sarah Newman; Lena Jorde; Tina Chabrashvili; Shiva Annamalai; Michele Esposito; Carey D Kimmelstiel; Tim Lenihan; Daniel Burkhoff
Journal:  Catheter Cardiovasc Interv       Date:  2019-05-21       Impact factor: 2.692

2.  Intermittent Occlusion of the Superior Vena Cava Reduces Cardiac Filling Pressures in Preclinical Models of Heart Failure.

Authors:  Navin K Kapur; Lara Reyelt; Paige Crowley; Lauren Richey; John McCarthy; Shiva Annamalai; Sarah Newman; Lena Jorde; Sina Forotuanjazi; Allen Razavi; Tim Lenihan; Daniel Burkhoff; Richard H Karas
Journal:  J Cardiovasc Transl Res       Date:  2019-11-26       Impact factor: 4.132

Review 3.  Gut Microbiome and Precision Nutrition in Heart Failure: Hype or Hope?

Authors:  Thanat Chaikijurajai; W H Wilson Tang
Journal:  Curr Heart Fail Rep       Date:  2021-02-09

Review 4.  Understanding the Pathobiology of Pulmonary Hypertension Due to Left Heart Disease.

Authors:  Jessica H Huston; Sanjiv J Shah
Journal:  Circ Res       Date:  2022-04-28       Impact factor: 23.213

5.  Concomitant Hepatorenal Dysfunction and Malnutrition in Valvular Heart Surgery: Long-Term Prognostic Implications for Death and Heart Failure.

Authors:  Yi-Kei Tse; Chanchal Chandramouli; Hang-Long Li; Si-Yeung Yu; Mei-Zhen Wu; Qing-Wen Ren; Yan Chen; Pui-Fai Wong; Ko-Yung Sit; Daniel Tai-Leung Chan; Cally Ka-Lai Ho; Wing-Kuk Au; Xin-Li Li; Hung-Fat Tse; Carolyn S P Lam; Kai-Hang Yiu
Journal:  J Am Heart Assoc       Date:  2022-05-16       Impact factor: 6.106

Review 6.  Gut Microbiota and Cardiovascular Disease.

Authors:  Marco Witkowski; Taylor L Weeks; Stanley L Hazen
Journal:  Circ Res       Date:  2020-07-30       Impact factor: 17.367

7.  Drug Targets for Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach and Review of Contemporary Clinical Trials.

Authors:  Ravi B Patel; Sanjiv J Shah
Journal:  Annu Rev Pharmacol Toxicol       Date:  2018-10-08       Impact factor: 13.820

8.  20th Annual Feigenbaum Lecture: Echocardiography for Precision Medicine-Digital Biopsy to Deconstruct Biology.

Authors:  Sanjiv J Shah
Journal:  J Am Soc Echocardiogr       Date:  2019-11       Impact factor: 5.251

Review 9.  A right ventricular state of mind in the progression of heart failure with reduced ejection fraction: implications for left ventricular assist device therapy.

Authors:  Ersilia M DeFilippis; Marco Guazzi; Paolo C Colombo; Melana Yuzefpolskaya
Journal:  Heart Fail Rev       Date:  2021-11       Impact factor: 4.214

Review 10.  The Gut in Heart Failure: Current Knowledge and Novel Frontiers.

Authors:  Antonella Gallo; Noemi Macerola; Angela Maria Favuzzi; Maria Anna Nicolazzi; Antonio Gasbarrini; Massimo Montalto
Journal:  Med Princ Pract       Date:  2022-01-28       Impact factor: 2.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.